HiFiBiO Therapeutics acquires H-Immune

HiFiBiO Therapeutics (Cambridge, Mass.) acquired H-Immune Therapeutics S.A.S. (Paris, France) for an undisclosed sum. H-Immune is developing a pipeline of immuno-oncology focused human antibodies generated using the company's in vitro immunization platform. The biotech spun out of the French Atomic Energy Commission in 2016. Founder Luc Boblet will join HiFiBiO as EVP of business development.

HiFiBiO President, CEO and CSO Liang Schweizer told BioCentury the combined company will "identify first-in-class targets for multiple immune cell types" and will generate a pipeline of antibodies to treat cancer and autoimmune disease. ...